Gefitinib With Pemetrexed Improves PFS in Non-small Cell Lung Cancer

Share this content:
The addition of pemetrexed to gefitinib improved progression-free survival for patients with non-small cell lung cancer.
The addition of pemetrexed to gefitinib improved progression-free survival for patients with non-small cell lung cancer.

The addition of pemetrexed to gefitinib improved progression-free survival (PFS) for patients with advanced, non-squamous, EGFR mutation-positive non-small cell lung cancer (NSCLC), a study published in the Journal of Clinical Oncology has shown.1

For this open-label study, researchers enrolled 195 chemotherapy-naive patients from 25 sites in China, Japan, Korea, and Taiwan. Participants were randomly assigned 2:1 to receive pemetrexed plus gefitinib or gefitinib alone.

Median PFS was 15.8 months with the combination, compared with 10.9 months with gefitinib alone (adjusted hazard ratio [aHR], 0.68; 95% CI, 0.48-0.96; P = .029).

Adding pemetrexed to gefitinib was associated with a longer time to disease progression (16.2 versus 10.9 months; HR, 0.66; 95% CI, 0.47-0.93) and a longer duration of response (15.4 versus 11.3 months; HR, 0.74; 95% CI, 0.50-1.08), than with gefitinib alone.

There was no significant difference in the tumor response rates between the 2 treatment arms; overall survival data are not yet reported.

RELATED: Study of Nivolumab in NSCLC Fails to Meet Primary Endpoint

Patients who received gefitinib with pemetrexed were more likely to experience treatment-related grade 3 to 4 adverse events, though the toxicities were manageable.                    

Reference

  1. Cheng Y, Murakami H, Yang PC, et al. Randomized phase II trial of gefitinib with and without pemetrexed as first-line therapy in patients with advanced nonsquamous non–small-cell lung cancer with activating epidermal growth factor receptor mutations. J Clin Oncol. 2016 Aug 8. doi: 10.1200/JCO.2016.66.9218 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters